



Substitute for form 1449A/PTO

AUG 12 2004

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	2	Attorney Docket No.	99,296-C
-------	---	----	---	---------------------	----------

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No. 1	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear	
		Number	Kind Code <sup>2</sup> (if known)				
CL		6,063,759					
CL		6,399,607	B1	Welch et al.	June 4, 2002		
OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No. 1	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published					T <sup>2</sup>
CL		ADACHI et al., "Cloning and Expression of Dipeptidase from Acinetobacter calcoaceticus ATCC 23055", <i>J. Biochem.</i> 118, 555-561 (1995).					
		BARRY et al., "Pathogenicity and Immunogenicity of Listeria monocytogenes Small-Plaque Mutants Defective for Intracellular Growth and Cell-to-Cell Spread" 1992, <i>Infect. Immun.</i> 60:1625-1632.					
		SUN et al., "Reduced Pyrazinamidase Activity and the Natural Resistance of Mycobacterium kansasii to the Antituberculosis Drug Pyrazinamide" <i>Antimicrobial Agents and Chemotherapy</i> 43(3)537-542 (Mar. 1999).					
		DENIS et al., "Killing of Mycobacterium smegmatis by Macrophages from Genetically Susceptible and Resistant Mice", 1990, <i>J. Leuk. Biol.</i> 47:25-29.					
		DREVETS AND CAMPBELL "Roles of Complement and Complement Receptor Type 3 in Phagocytosis of Listeria monocytogenes by Inflammatory Mouse Peritoneal Macrophages", 1991, <i>Infect. Immun.</i> 59:517-523.					
		DREVETS et al., "Listericidal and nonlistericidal mouse macrophages differ in complement receptor type 3-mediated phagocytosis of L. monocytogenes and in preventing escape of the bacteria into the cytoplasm", 1992, <i>J. Leuk. Biol.</i> 52:70-79.					
		HEIFETS et al., "Does Pyrazinoic Acid as an Active Moiety of Pyrazinamide Have Specific Activity against Mycobacterium tuberculosis", 1989, <i>Antimicrob. Agents, Chemother.</i> 33:1232-1234.					
		HOASHI et al., 1999, <i>Kekkaku</i> 74:441-445					
		HOU et al., "Molecular Characterization of pncA gene mutations in Mycobacterium tuberculosis clinical isolates from China", 2000, <i>Epidemiol. Infect.</i> 124:227-232.					
		KABAT et al., 1988, <i>Chem. Pharm. Bull.</i> 36:634-640					
Examiner Signature	<i>CL Welch</i>				Date Considered	5-30-03	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

Substitute for form 1449A/PTO

Complete if Known

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application No.	
Filing Date:	November 5, 2001
First Named Inventor	Yatvin et al.
Group Art Unit	1614
Examiner Name	K. Weddington

Sheet	2	of	2	Attorney Docket No.	99,296-C
-------	---	----	---	---------------------	----------

### OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. 1	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
CL		KUSHNER et al., "Experimental Chemotherapy of Tuberculosis. II. The Synthesis of Pyrazinamides and Related Compounds: 1952, J. Amer. Chem. Soc. 74:3617-3621.	
		MACKALL et al., "A Mild Procedure for the Rapid Release of Cytoplasmic Enzymes from Cultured Animal Cells", 1979, <i>Analyt. Biochem.</i> 95:270-274.	
		MARTILLA et al., "pncA Mutations in Pyrazinamide-Resistant <i>Mycobacterium tuberculosis</i> Isolated from Northwestern Russia", 1999, <i>Antimicrob. Agents Chemother.</i> 43:1764-1766.	
		MESTDAGH et al., "Relationship between Pyrazinamide Resistance, Loss of Pyrazinamidase Activity, and Mutations in the pncA Locus in Multidrug-Resistant Clinical Isolates of <i>Mycobacterium tuberculosis</i> ", 1999, <i>Antimicrob. Agents Chemother.</i> 43:2317-2319.	
		MINIYAR AND BHAT, "Pyrazinoic Acid Hydrazide Derivatives: Synthesis and Antimycobacterial Activities", <i>Indian Journal of Heterocyclic Chemistry</i> , vol. 9, Oct.-Dec. 1999, pp. 155-156.	
		NIBBERING et al., "Bacteriostatic Activity of BCG/PPD-Activated Macrophages Against <i>Mycobacterium fortuitum</i> Does Not Involve Reactive Nitrogen or Oxygen Intermediates", 1994, <i>Scand. J. Immunol.</i> 40:187.	
		PECK, "A One-Plate Assay for Macrophage Bactericidal Activity", 1985, <i>J. Immunol. Methods</i> 82:131-140.	
		RADZIOCH et al., "Genetic Resistance/Susceptibility to Mycobacteria: Phenotypic Expression in Bone Marrow Derived Macrophage Lines", 1991, <i>J. Leuk. Biol.</i> 50:263.	
		RAYNAUD et al., "Mechanisms of pyrazinamide resistance in mycobacteria: importance of lack of uptake in addition to lack of pyrazinamidase activity", 1999, <i>Microbiol.</i> 145:1359-1367.	
		SHETTY et al., "Occurrence of $\gamma$ -Glutamyl Transpeptidase Activity in Several Mycobacteria Including <i>Mycobacterium leprae</i> ", 1981, <i>Intl. J. Lepr. Other Mycobact. Dis.</i> 49:49-56.	
		SING et al., "Severe Cutaneous <i>Mycobacterium chelonei</i> infection following a yellow jacket sting", 1992, <i>Tubercle &amp; Lung Dis.</i> 73:305.	
		STEVEN et al., "Mycobacterium fortuitum Keratitis. A Comparison of Topical Ciprofloxacin and Amikacin in an Animal Model", 1992, <i>Cornea</i> 11:500.	
		VAN FURTH et al., "Mycobacteria and Macrophage Activation" 1990, <i>Res. Microbiol.</i> 141:256.	
Examiner Signature		Date Considered	5-30-01

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231